Click on headlines below to download research

Preparing for DNV3837 Phase II trial start
Deinove | 25/04/2019

With its latest H218 report, Deinove reiterated its focus on the major areas of bioactives and antibiotics. The most recent significant announcement was…

Diversified biotech championing antibiotics
Deinove | 14/03/2019

Deinove is a biotech company that develops innovative compounds from rare bacteria strains, including the little-explored Deinococcus genus. Using proprietary…

Cash conservation and operational progress
Deinove | 23/10/2017

A refocused business, a strengthened management team and progress with its underlying research programmes suggest Deinove is on course to generate commercial…